Background: Endobronchial ultrasound (EBUS)-guided intranodal forceps biopsy (IFB), a diagnostic bronchoscopic technique for intrathoracic lymphadenopathy, is performed following EBUS-guided transbronchial needle aspiration (TBNA). The current EBUS-IFB technique is complex and provides small sample volumes. We modified this technique to allow the use of standard-sized forceps. Objectives: The aim of this study was to assess the feasibility of the modified EBUS-IFB technique, which combines standard-sized forceps with standard EBUS-TBNA equipment. Method: This retrospective analysis included consecutive patients scheduled for EBUS-TBNA with attempted additional IFB between July 2020 and March 2021. The feasibility indices of IFB, technical success rate, diagnostic accuracy, and major complications were retrospectively investigated. We performed semi-quantitative evaluation of the histological specimens and univariable analyses to identify factors associated with IFB failure. Results: During the study period, 295 patients underwent 307 EBUS-TBNAs; 195 cases were included in the analyses. Target lesions were mainly mediastinal lymph nodes (134 cases, 68.7%); the most frequent sites were #7 (61 cases) and #4R (50 cases). The median lesion size was 16.1 mm, the technical IFB success rate was 90.8%, and the diagnostic accuracy of the TBNA and IFB combination was 99.5%. One patient was lost to follow-up. Univariable analyses did not identify any factors involved in technical IFB failure. Major complications of pneumonia and pneumothorax occurred in 2 cases (1.0%). The median histological score was significantly higher in the IFB group than in the TBNA group (1.67 vs. 1.50, p = 0.032). Conclusions: Modified EBUS-IFB, combining standard-sized forceps with common EBUS-TBNA equipment, is feasible with few major complications.

1.
Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive Summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl l):7S–37S.
2.
Wahidi MM, Herth F, Yasufuku K, Shepherd RW, Yarmus L, Chawla M, et al. Technical aspects of endobronchial ultrasound-guided transbronchial needle aspiration: CHEST guideline and expert panel report. Chest. 2016 Mar;149(3):816–35.
3.
Gu P, Zhao YZ, Jiang LY, Zhang W, Xin Y, Han BH. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer. 2009 May;45(8):1389–96.
4.
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018 Jan 11;378(2):113–25.
5.
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017 Jul 1;390(10089):29–39.
6.
Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, et al. Crizotinib in ROS1-rearranged advanced Non-Small-Cell Lung Cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019 Jul 1;30(7):1121–6.
7.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984–93.
8.
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020 Sep 3;383(10):931–43.
9.
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017 Jun;23(6):703–13.
10.
Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 Nov 20;38(33):3883–94.
11.
Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, et al. Multiplex gene-panel testing for lung cancer patients. Pathol Int. 2020 Dec;70(12):921–31.
12.
Takeda M, Takahama T, Sakai K, Shimizu S, Watanabe S, Kawakami H, et al. Clinical application of the FoundationOne CDx assay to therapeutic decision-making for patients with advanced solid tumors. Oncologist. 2021 Apr;26(4):e588–96.
13.
Xie F, Zheng X, Mao X, Zhao R, Ye J, Zhang Y, et al. Next-generation sequencing for genotyping of endobronchial ultrasound-guided transbronchial needle aspiration samples in lung cancer. Ann Thorac Surg. 2019 Jul;108(1):219–26.
14.
Martin-Deleon R, Teixido C, Lucena CM, Martinez D, Fontana A, Reyes R, et al. EBUS-TBNA cytological samples for comprehensive molecular testing in non-small cell lung cancer. Cancers. 2021 Apr 25;13(9):2084.
15.
Dooms C, Vander Borght S, Yserbyt J, Testelmans D, Wauters E, Nackaerts K, et al. A randomized clinical trial of flex 19G needles versus 22G needles for endobronchial ultrasonography in suspected lung cancer. Respiration. 2018;96(3):275–82.
16.
Tajarernmuang P, Ofiara L, Beaudoin S, Wang H, Benedetti A, Gonzalez AV. Real-world outcomes of patients with advanced non-small cell lung cancer treated with anti-PD1 therapy on the basis of PD-L1 results in EBUS-TBNA vs histological specimens. Chest. 2021 Aug;160(2):743–53.
17.
Layfield LJ, Roy-Chowdhuri S, Baloch Z, Ehya H, Geisinger K, Hsiao SJ, et al. Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: the papanicolaou society of cytopathology consensus recommendations for respiratory cytology. Diagn Cytopathol. 2016 Dec;44(12):1000–9.
18.
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823–33.
19.
Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020–31.
20.
Noll B, Wang WL, Gong Y, Zhao J, Kalhor N, Prieto V, et al. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. Cancer Cytopathol. 2018 May;126(5):342–52.
21.
Herth FJF, Morgan RK, Eberhardt R, Ernst A. Endobronchial ultrasound-guided miniforceps biopsy in the biopsy of subcarinal masses in patients with low likelihood of non-small cell lung cancer. Ann Thorac Surg. 2008 Jun;85(6):1874–8.
22.
Mehta RM, Aurangabadbadwalla R, Singla A, Loknath C, Munavvar M. Endobronchial ultrasound-guided mediastinal lymph node forceps biopsy in patients with negative rapid-on-site-evaluation: a new step in the diagnostic algorithm. Clin Respir J. 2020 Apr;14(4):314–9.
23.
Ray AS, Li C, Murphy TE, Cai G, Araujo KLB, Bramley K, et al. Improved diagnostic yield and specimen quality with endobronchial ultrasound-guided forceps biopsies: a retrospective analysis. Ann Thorac Surg. 2020 Mar;109(3):894–901.
24.
Gasparini S, Zuccatosta L, Sediari M, Mei F. Pilot feasibility study of transbronchial needle forceps: a new tool for obtaining histology samples from mediastinal subcarinal lymph nodes. J Bronchology Interv Pulmonol. 2009 Jul;16(3):183–7.
25.
Herth FJF, Schuler H, Gompelmann D, Kahn N, Gasparini S, Ernst A, et al. Endobronchial ultrasound-guided lymph node biopsy with transbronchial needle forceps: a pilot study. Eur Respir J. 2012 Feb;39(2):373–7.
26.
Darwiche K, Freitag L, Nair A, Neumann C, Karpf-Wissel R, Welter S, et al. Evaluation of a novel endobronchial ultrasound-guided lymph node forceps in enlarged mediastinal lymph nodes. Respiration. 2013;86(3):229–36.
27.
Oki M, Saka H, Sako C. Bronchoscopic miniforceps biopsy for mediastinal nodes. J Bronchology. 2004 Jul;11(3):150–3.
28.
Chrissian A, Misselhorn D, Chen A. Endobronchial-ultrasound guided miniforceps biopsy of mediastinal and hilar lesions. Ann Thorac Surg. 2011 Jul;92(1):284–8.
29.
Franke KJ, Bruckner C, Nilius G, Ruhle KH. Investigation of the flexibility of bronchoscopes. Eur J Med Res. 2011 Sep12;16(9):420–4.
30.
Fujiwara T, Yasufuku K, Nakajima T, Chiyo M, Yoshida S, Suzuki M, et al. The utility of sonographic features during endobronchial ultrasound-guided transbronchial needle aspiration for lymph node staging in patients with lung cancer: a standard endobronchial ultrasound image classification system. Chest. 2010 Sep;138(3):641–7.
31.
Nakajima T, Anayama T, Shingyoji M, Kimura H, Yoshino I, Yasufuku K. Vascular image patterns of lymph nodes for the prediction of metastatic disease during EBUS-TBNA for mediastinal staging of lung cancer. J Thorac Oncol. 2012 Jun;7(6):1009–14.
32.
Izumo T, Sasada S, Chavez C, Matsumoto Y, Tsuchida T. Endobronchial ultrasound elastography in the diagnosis of mediastinal and hilar lymph nodes. Jpn J Clin Oncol. 2014 Oct;44(10):956–62.
33.
Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009 May;4(5):568–77.
34.
Bramley K, Pisani MA, Murphy TE, Araujo KL, Homer RJ, Puchalski JT. Endobronchial ultrasound-guided cautery-assisted transbronchial forceps biopsies: safety and sensitivity relative to transbronchial needle aspiration. Ann Thorac Surg. 2016 May;101(5):1870–6.
35.
Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021 Mar 19;14(1):45.
36.
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022 Feb 14;40(2):201–18. e9
37.
Cheng G, Mahajan A, Oh S, Benzaquen S, Chen A. Endobronchial ultrasound-guided intranodal forceps biopsy (EBUS-IFB)-technical review. J Thorac Dis. 2019 Sep;11(9):4049–58.
38.
Radchenko CC, Cho PK, Kang L, Saettele TM. Performance of endobronchial-ultrasound guided miniforceps biopsy of targeted mediastinal and hilar lesions. Respir Med. 2019 Oct-Nov;158:92–6.
39.
Trisolini R, Lazzari Agli L, Cancellieri A, Poletti V, Tinelli C, Baruzzi G, et al. The value of flexible transbronchial needle aspiration in the diagnosis of stage I sarcoidosis. Chest. 2003 Dec;124(6):2126–30.
40.
Erer OF, Erol S, Anar C, Aydoğdu Z, Ozkan SA. Diagnostic yield of EBUS-TBNA for lymphoma and review of the literature. Endosc Ultrasound. 2017 Sep-Oct;6(5):317–22.
41.
Gonuguntla HK, Shah M, Gupta N, Agrawal S, Poletti V, Nacheli GC. Endobronchial ultrasound-guided transbronchial cryo-nodal biopsy: a novel approach for mediastinal lymph node sampling. Respirol Case Rep. 2021Jul 8;9(8):e00808.
42.
Zhang J, Guo JR, Huang ZS, Fu WL, Wu XL, Wu N, et al. Transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: a randomised trial. Eur Respir J. 2021 Dec9;58(6):2100055.
You do not currently have access to this content.